

Material information

Date	06 December 2021
Name of the Listed Company	Gulf Pharmaceutical Industries-Julphar
The Material Information	Julphar signs an exclusive license and production agreement with Quantum Genomics for firibastat, a first-in-class drug for resistant and difficult to treat hypertension and for heart failure. Julphar will be the exclusive manufacturing and commercialization partner for firibastat in MENA, all African countries, CIS and Turkey.
The expected effect of material information on the financial position and results of the company's business and operations	Firibastat addresses up to 25% of the hypertension market which is estimated at USD 1.2bio for MENA region and Turkey in 2020. The product is expected to contribute substantially to Julphar's sales and profit performance after its market launch in 2024. Julphar agreed to USD 5m upfront & development milestone payments and USD 2m equity investment during the development phase plus royalties and sales milestone payments during the commercialization of the product.
The financial period in which the financial impact will appear	Market launch is expected in 2024. Product development milestone payments and equity investment are expected for the years 2022-2024

The Name of the Authorized Signatory	Juergen Lauterbach
Designation	Chief Financial and Strategy Officer
Signature and Date	06 December 2021 